Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
28 11 2019
Historique:
received: 09 12 2016
revised: 09 03 2017
accepted: 23 03 2017
pubmed: 26 6 2017
medline: 30 9 2020
entrez: 26 6 2017
Statut: ppublish

Résumé

Development of a vaccine against herpes simplex virus (HSV) is an important goal for global sexual and reproductive health. In order to more precisely define the health and economic burden of HSV infection and the theoretical impact and cost-effectiveness of an HSV vaccine, in 2015 the World Health Organization convened an expert consultation meeting on HSV vaccine impact modelling. The experts reviewed existing model-based estimates and dynamic models of HSV infection to outline critical future modelling needs to inform development of a comprehensive business case and preferred product characteristics for an HSV vaccine. This article summarizes key findings and discussions from the meeting on modelling needs related to HSV burden, costs, and vaccine impact, essential data needs to carry out those models, and important model components and parameters.

Identifiants

pubmed: 28647165
pii: S0264-410X(17)30408-5
doi: 10.1016/j.vaccine.2017.03.074
pmc: PMC10599163
mid: NIHMS1935541
pii:
doi:

Substances chimiques

Herpes Simplex Virus Vaccines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

7336-7345

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : P01 AI030731
Pays : United States

Informations de copyright

Copyright © 2017. Published by Elsevier Ltd.

Références

Sex Transm Infect. 2007 Aug;83 Suppl 1:i17-24
pubmed: 17405782
MDM Policy Pract. 2016 Jul 07;1(1):2381468316642238
pubmed: 30288400
N Engl J Med. 1999 Nov 4;341(19):1432-8
pubmed: 10547406
Clin Perinatol. 2015 Mar;42(1):47-59, viii
pubmed: 25677996
N Engl J Med. 2002 Nov 21;347(21):1652-61
pubmed: 12444179
Vaccine. 2016 Jun 3;34(26):2939-2947
pubmed: 27105564
AIDS. 2006 Jan 2;20(1):73-83
pubmed: 16327322
Sex Transm Dis. 2010 May;37(5):290-7
pubmed: 20351622
Am J Obstet Gynecol. 2005 Sep;193(3 Pt 2):1274-9
pubmed: 16157151
Lancet. 2007 Dec 22;370(9605):2127-37
pubmed: 18156035
Am J Obstet Gynecol. 2004 Dec;191(6):2074-84
pubmed: 15592294
J Infect Dis. 2005 May 15;191(10):1734-46
pubmed: 15838802
Sex Transm Dis. 2000 Aug;27(7):363-70
pubmed: 10949427
Lancet. 2015 Aug 22;386(9995):743-800
pubmed: 26063472
J Pediatr Nurs. 2015 Mar-Apr;30(2):346-52
pubmed: 25193688
Vaccine. 2009 Feb 5;27(6):940-6
pubmed: 19071187
Sex Transm Dis. 2003 Feb;30(2):174-7
pubmed: 12567178
Pediatrics. 2011 Jan;127(1):e1-8
pubmed: 21149432
Vaccine. 2014 Mar 20;32(14):1630-7
pubmed: 24480024
Semin Pediatr Infect Dis. 2005 Jan;16(1):17-23
pubmed: 15685145
Vaccine. 2016 Jun 3;34(26):2948-2952
pubmed: 26973067
Vaccine. 2014 Mar 20;32(14):1536-42
pubmed: 24606635
PLoS One. 2015 Jan 21;10(1):e114989
pubmed: 25608026
PLoS One. 2015 Oct 28;10(10):e0140765
pubmed: 26510007
JAMA. 2003 Jan 8;289(2):203-9
pubmed: 12517231
Hum Vaccin. 2007 Nov-Dec;3(6):231-8
pubmed: 17881889
Sex Transm Infect. 2004 Feb;80(1):24-9
pubmed: 14755031
BMC Public Health. 2011 Jul 05;11:534
pubmed: 21729309
J R Soc Interface. 2014 Mar 26;11(95):20140160
pubmed: 24671939
Ann Intern Med. 1992 Feb 1;116(3):197-202
pubmed: 1309413
Am J Manag Care. 1997 Oct;3(10):1551-8
pubmed: 10178461
Vaccine. 2014 Mar 20;32(14):1527-35
pubmed: 24581979
Sex Transm Infect. 2005 Jun;81(3):267-70
pubmed: 15923300
Lancet Glob Health. 2017 Mar;5(3):e300-e309
pubmed: 28153513
Ann Intern Med. 2005 Nov 15;143(10):707-13
pubmed: 16287791
N Engl J Med. 2012 Jan 5;366(1):34-43
pubmed: 22216840
JAMA. 1999 Jul 28;282(4):331-40
pubmed: 10432030
Sex Transm Dis. 2013 Mar;40(3):197-201
pubmed: 23403600
AIDS. 2015 Jun 1;29(9):1077-85
pubmed: 26125141
Sex Transm Infect. 2011 Mar;87(2):141-8
pubmed: 21097810
BMC Infect Dis. 2001;1:5
pubmed: 11472635
Sex Transm Dis. 2002 Oct;29(10):608-22
pubmed: 12370529
PLoS One. 2012;7(10):e46027
pubmed: 23071536
PLoS One. 2015 Apr 22;10(4):e0125018
pubmed: 25901355
Clin Infect Dis. 2013 Feb;56(3):344-51
pubmed: 23087395
Herpes. 2004 Apr;11 Suppl 1:36A-45A
pubmed: 15115628
PLoS One. 2008 May 21;3(5):e2230
pubmed: 18493617
Herpes. 2004 Aug;11 Suppl 3:170A-174A
pubmed: 15319087

Auteurs

Sami L Gottlieb (SL)

World Health Organization (WHO), Geneva, Switzerland. Electronic address: gottliebs@who.int.

Birgitte Giersing (B)

World Health Organization (WHO), Geneva, Switzerland.

Marie-Claude Boily (MC)

Imperial College, London, UK.

Harrell Chesson (H)

Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.

Katharine J Looker (KJ)

University of Bristol, UK.

Joshua Schiffer (J)

University of Washington, Seattle, WA, USA.

Ian Spicknall (I)

Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.

Raymond Hutubessy (R)

World Health Organization (WHO), Geneva, Switzerland.

Nathalie Broutet (N)

World Health Organization (WHO), Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH